Ethyl-2,2-difluoro-2-(3-chlorophenyl)-acetate, 95.0%, 5g

2-(Naphthalen-2-yl)-2-oxoacetic acid, 95%, 500mg

4-Iodo-3-methylbenzonitrile, 95+%, 2g

Infinity corrected plan phase S100x/1.25 objective. Working distance 0.18 mm

1,4-Phenylene di-tert-butyl bis(carbonate), 98%, 5g

2-Amino-4-(2,5-dimethylphenyl)-5-methylthiophene-3-carboxylic acid methyl ester, 95.0%, 1g

5-(4-(isopropylthio)benzyl)-1,3,4-oxadiazol-2-amine, 95.0%, 1g

8-Bromo-2-methoxy-1,5-naphthyridine, 95.0%, 5g

1H-Pyrazole-3,5-diamine, 95.0%, 250mg

methyl 5-formylpyridine-3-carboxylate, 95.0%, 100mg

6-Bromo-1-isopropyl-2-methyl-1H-benzo[d]imidazole, 95.0%, 1g

(R)-Morpholine-3-carboxylic acid, 95.0%, 5g

N-METHYL-N-[(3S)-PYRROLIDIN-3-YL]METHANESULFONAMIDE HCL, 95.0%, 1g